Semnur Pharmaceuticals Inc (SMNR)
Health CareSnapshot 2026-11-04
$0.50-9.02%
Close 2026-09-04 · 1-day change
Health CareSnapshot 2026-11-04
QuarterlyIQ Insights · SMNR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete the proposed $100 million equity investment from iHolding Group LLP to support company operations and growth.
Newly stated in 2026-Q2. Management announced a binding term sheet for a $100 million equity investment from iHolding Group LLP. There is no prior quarter mention. The financials show ongoing net losses and negative operating income, indicating the investment is critical. The trajectory is newly established with no delivery yet.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Entered into a binding term sheet with iHolding Group LLP for a $100 million equity investment.”
Continue efforts to control and reduce net losses and operating expenses amid ongoing negative income results.
Stated in 8 of last 8 quarters. Net income improved from negative $152.59 million in 2025-Q3 to negative $4.35 million in 2026-Q2, and operating income improved similarly. Management continues to report losses but the trajectory shows significant reduction in losses, indicating progress managing expenses.
“Net income was negative $4.35 million and operating income negative $4.22 million.”
“Net income and operating income were negative $4.58 million each.”
“Net income and operating income were negative $6.16 million each.”
“Net income and operating income were negative $152.59 million each.”
“Net income was negative $0.39 million and operating income negative $0.37 million.”
“Net income was negative $0.19 million and operating income negative $0.25 million.”
“Net income was negative $0.17 million and operating income negative $2.86 million.”
“Net income was negative $0.04 million and operating income negative $0.21 million.”
Manage leadership transition with retiring CEO and named internal successor to maintain company stability.
Newly stated in 2026-Q1. Management announced the CEO retirement with an immediate internal successor named. This priority is recent with no prior mentions. The financials show ongoing losses but no direct impact from leadership change is quantifiable yet. The trajectory is newly established.
“CEO retiring with immediate, named internal successor Henry Ji.”
Manage the impact and next steps following termination of a material definitive agreement related to M&A activity.
Newly stated in 2026-Q2. Management disclosed termination of a material definitive agreement from the prior business combination. There is no prior mention. Financials show continuing losses but no direct financial impact from this event is quantifiable. The trajectory is newly established.
“Termination of a Material Definitive Agreement related to the business combination.”
Over the trailing year it converted 0.83x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, Fed net liquidity, long-term interest rates (low R² over the window).
24 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.